Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.

Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies

Open access
Cupp, Meghan A., Cariolou, Margarita, Tzoulaki, Ioanna, Aune, Dagfinn, Evangelou, Evangelos, Berlanga-Taylor, Antonio J. · 2020 · BMC Medicine

Published version of a preprint

Abstract

Background: Although neutrophils have been linked to the progression of cancer, uncertainty exists around their association with cancer outcomes, depending on the site, outcome and treatments considered. We aimed to evaluate the strength and validity of evidence on the association between either the neutrophil to lymphocyte ratio (NLR) or tumour-associated neutrophils (TAN) and cancer prognosis. Methods: We searched MEDLINE, Embase and Cochrane Database of Systematic Reviews from inception to 29 May 2020 for systematic reviews and meta-analyses of observational studies on neutrophil counts (here NLR or TAN) and specific cancer outcomes related to disease progression or survival. The available evidence was graded as strong, highly suggestive, suggestive, weak or uncertain through the application of pre-set GRADE criteria. Results: A total of 204 meta-analyses from 86 studies investigating the association between either NLR or TAN and cancer outcomes met the criteria for inclusion. All but one meta-analyses found a hazard ratio (HR) which increased risk (HR > 1). We did not find sufficient meta-analyses to evaluate TAN and cancer outcomes ( N = 9). When assessed for magnitude of effect, significance and bias related to heterogeneity and small study effects, 18 (9%) associations between NLR and outcomes in composite cancer endpoints (combined analysis), cancers treated with immunotherapy and some site specific cancers (urinary, nasopharyngeal, gastric, breast, endometrial, soft tissue sarcoma and hepatocellular cancers) were supported by strong evidence. Conclusion: In total, 60 (29%) meta-analyses presented strong or highly suggestive evidence. Although the NLR and TAN hold clinical promise in their association with poor cancer prognosis, further research is required to provide robust evidence, assess causality and test clinical utility. Trial registration: PROSPERO CRD42017069131 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-020-01817-1

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of systematic review and meta-analysis selection
Fig. 1 Flowchart of systematic review and meta-analysis selectionCC BY · PubMed Central
Fig. 2 Assessment of consistency in meta-analyses. a Log (HR) of largest study versus log (HR) of random effects estimates for each meta-analysis. The Y-axis labelled “log (HR) Largest Study” represents the log of the HR of the largest component study. The X-axis labelled “log (HR) Random Effects” represents the log of the HR of the random effects estimate calculated in each meta-analysis. b Random effects estimates versus inverse variance. The Y-axis labelled “Random Effects Estimates Hazard Ratio” represents the HR of random effects estimate for each meta-analysis. The X-axis labelled “Inverse Variance” represents the inverse of the variance for each meta-analysis. c, d Box plots of random effects HR estimates for each meta-analysis by cancer site and outcome. The Y-axis labelled “HR” details the effect size for each meta-analysis describing an association between NLR or TAN and cancer prognosis for each site grouping. The X-axis labelled “Site” in c represents each site group meta-analyses have been sorted into. The composite endpoints subgroup is defined as a grouping of cancer diagnosis unrelated to site, stage or treatment. The X-axis labelled “Outcome” in d represents the prognostic outcome assessed in each meta-analysis. The outlier of HR = 14 for NLR and OS in rectal cancer has been excluded from these figures
Fig. 2 Assessment of consistency in meta-analyses. a Log (HR) of largest study versus log (HR) of random effects estimates for each meta-analysis. The Y-axis labelled “log (HR) Largest Study” represents the log of the HR of the largest component study. The X-axis labelled “log (HR) Random Effects” represents the log of the HR of the random effects estimate calculated in each meta-analysis. b Random effects estimates versus inverse variance. The Y-axis labelled “Random Effects Estimates Hazard Ratio” represents the HR of random effects estimate for each meta-analysis. The X-axis labelled “Inverse Variance” represents the inverse of the variance for each meta-analysis. c, d Box plots of random effects HR estimates for each meta-analysis by cancer site and outcome. The Y-axis labelled “HR” details the effect size for each meta-analysis describing an association between NLR or TAN and cancer prognosis for each site grouping. The X-axis labelled “Site” in c represents each site group meta-analyses have been sorted into. The composite endpoints subgroup is defined as a grouping of cancer diagnosis unrelated to site, stage or treatment. The X-axis labelled “Outcome” in d represents the prognostic outcome assessed in each meta-analysis. The outlier of HR = 14 for NLR and OS in rectal cancer has been excluded from these figuresCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 157 references

Research works printed but not linked: 6

  1. Reichardt C. RefWorks: http://www.refworks.com. Public Services Quarterly. 2010;6(4):366–7.
  2. Schwarzer G. meta: An R package for meta-analysis. R news. 2007;7(3):40–5.
  3. StataCorp. Stata statistical software: release 14. College Station: StataCorp LP; 2015.
  4. Zheng DC, Zheng C, Wu J, et al. Neutrophil-lymphocyte ratio predicts the prognosis of patients with colorectal cancer: a meta-analysis. Int J Clin Exp Med. 2015;9(1):78–90.
  5. Dolan RD, McSorley ST, Horgan PG, et al. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;116(1):134–46.
  6. Zhou Y, Cheng S, Fathy AH, et al. Prognostic value of platelet-tolymphocyte ratio in pancreatic cancer: A comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther. 2018;11:1899–908. · DOI

Cited by

See all 699

Metadata

Authors
Cupp, M. A., Cariolou, M., Tzoulaki, I., Aune, D., Evangelou, E., & Berlanga-Taylor, A. J.
Affiliations
  • MRC Centre for Environment and Health (GB)
  • University of Ioannina (GR)
  • Oslo University Hospital (NO)
Venue
BMC Medicine
Published
2020-11-20
Volume
18
Issue
1
Pages
360-360
ISSN
1741-7015 (ISSN-L)
OpenAlex
W3104254817
Cited by
697
References
157
Citations by year
2026: 110 · 2025: 166 · 2024: 184 · 2023: 111 · 2022: 95 · 2021: 30
FWCI
6.34
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
Medical Research Council (MR/L01632X/1)
Topics
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
neutrophil-to-lymphocyte ratio, tumor-associated neutrophils, cancer prognosis, neutrophils, immunotherapy, cancer survival, disease progression
MeSH terms
Female, Humans, Lymphocytes, Male, Neoplasms, Neutrophils, Prognosis, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. https://app.cochat.ai/papers/10.1186/s12916-020-01817-1
The paper
Cupp, M. A., Cariolou, M., Tzoulaki, I., Aune, D., Evangelou, E., & Berlanga-Taylor, A. J. (2020). Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Medicine. https://doi.org/10.1186/s12916-020-01817-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.